Drug intelligence / Profile preview

NOVO118

Development stage: Preclinical
Lead developer: Novoron Bioscience
Modality: Small Molecules
Administration: Subcutaneous, Intravenous, Intrathecal

Overview

NOVO118 is a preclinical small-molecule inhibitor developed by Novoron Bioscience. It is being advanced for Alzheimer's drug discovery, specifically targeting LRP1-mediated tau spread. The goal for NOVO118 is to generate more predictive, human-relevant data to de-risk drug candidates prior to IND-enabling studies, addressing the high failure rate of Alzheimer's drugs developed with traditional models.

Targets

LRP1 (Prolow-density lipoprotein receptor-related protein 1)

Beyond the preview

Go deeper on NOVO118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOVO118.

Explore the full profile